The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Puchinskaya M.V.

Belarusian State Medical University, Minsk, Republic of Belarus

Cancer stem cell markers and their prognostic value

Authors:

Puchinskaya M.V.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2016;78(2): 47‑54

DOI: 10.17116/patol201678247-54

Views: 5262

Downloaded: 1461

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Puchinskaya MV. Cancer stem cell markers and their prognostic value. Russian Journal of Archive of Pathology. 2016;78(2):47‑54. (In Russ.)
https://doi.org/10.17116/patol201678247-54

Подписка 2025 (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Close metadata
Recommended articles:
ALDH1, CD133, CD34-positive cancer stem cells in lung adenocarcinoma in patients who had a new coro­navirus infe­ction and retained the persistence of viral proteins in the lung tissue. Russian Journal of Archive of Pathology. 2024;(5):5-14
Is it possible to detect surface anti­gen CD133 on patient-derived glioblastoma continuous cell cultures using fluorescent apta­mers?. Burdenko's Journal of Neurosurgery. 2024;(1):56-62
The role of ferroptosis in reproduction. A modern view of the problem. Russian Journal of Human Reproduction. 2024;(5):35-45

Based on an analysis of a large number of sources of literature, the paper gives general information on the markers for cancer stem cells (CSCs), which allow the detection of this rare cell subpopulation, on the possibilities of estimating their immunohistochemical or immunofluorescent expression in tumors, and on the prognostic and predictive values of these molecules. For their detection, investigators generally use definite molecules, the so-called markers of CSCs, among which there are CD44, CD133, CD24, aldehyde dehydrogenase, and others. The expression of these molecules in the tumor tissue obtained from patients affects survival rates and permits the prediction of a response to therapy. A better insight into the immunophenotype of CSCs, the role of CSC markers in retaining the special properties of this cell population, and the clinical significance of the expression of CSC markers will be able to elaborate new approaches to therapy for malignancies.

Keywords:

cancer stem cells
markers
CD44
CD133
prognostic value

Authors:

Puchinskaya M.V.

Belarusian State Medical University, Minsk, Republic of Belarus

List of references:

  1. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells — perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006;66:9339-9344. doi:10.1158/0008-5472.CAN-06-3126.
  2. Liu HG, Zhang XH. How to estimate cancer stem cell frequency correctly. Asian Pacific Journal of Cancer Prevention. 2009;10:711-714.
  3. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275-291.  doi:10.1016/j.stem.2014.02.006.
  4. Keysar S, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Molecular Cancer Therapeutics. 2010;9(9):2450-2457. doi:10.1158/1535-7163.MCT-10-0530.
  5. Fabian A, Vereb G, Szollosi J. The hitchhikers guide to cancer stem cell theory: markers, pathways and therapy. Cytometry Part A. 2013;83A:62-71.  doi:10.1002/cyto.a.22206.
  6. Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell. 2007;1:607-611.  doi:10.1016/j.stem.2007.11.009.
  7. Campos B, Herold-Mende CC. Insight into the complex regulation of CD133 in glioma. International Journal of Cancer. 2011;128(3):501-510.  doi:10.1002/ijc.25687.
  8. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133– metastatic colon cancer cells initiate tumors. Journal of Clinical Investigation. 2008;118(6):2111-2120. doi:10.1172/JCI34401.
  9. Garvalov BK, Acker T. Cancer stem cells: a new framework for the design of tumor therapies. Journal of Molecular Medicine. 2011;89:95-107.  doi:10.1007/s00109-010-0685-3.
  10. Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. Journal of Clinical Pathology. 2011;64(11):937-946.  doi:10.1136/jcp.2011.090456.
  11. Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Experimental Biology and Medicine (Maywood). 2013;238(3):324-338.  doi:10.1177/1535370213480714.
  12. Louderbough JMV, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Molecular Cancer Research. 2011;9(12):1573-1586. doi:10.1158/1541-7786.MCR-11-0156.
  13. Gao AC, Lou W, Dong JT, Isaacs JT. CD44 Is a metastasis supressor gene for prostatic cancer located on human chromosome 11p13. Cancer Research. 1997;57:846-849.
  14. Chen K, Huang YH, Chen JI. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacologica Sinica. 2013;34:732-740.  doi:10.1038/aps.2013.27.
  15. Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013;32:5191-5198. doi:10.1038/onc.2012.638.
  16. Yu X, Lin Y, Yan X, Tian Q, Li L, Lin EH. CD133, stem cells, and cancer stem cells: myth or reality? Current Colorectal Cancer Reports. 2011;7(4):253-259.  doi:10.1007/s11888-011-0106-1.
  17. Lingala S, Cui YY, Chen X, Ruebner BH, Qian XF, Zern MA, Wu J. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Experimental and Molecular Pathology. 2010;89(1):27-35.  doi:10.1016/j.yexmp.2010.05.005.
  18. Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell and Tissue Research. 2005;319(1):15-26.  doi:10.1007/s00441-004-1018-z.
  19. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Research. 2010;70(2):719-729.  doi:10.1158/0008-5472.CAN-09-1820.
  20. Ying X, Wu J, Meng X, Zuo Y, Xia Q, Chen J, Feng Y, Liu R, Li L, Huang W. AC133 expression associated with poor prognosis in stage II colorectal cancer. Medical Oncology. 2013;30(1):356.  doi:10.1007/s12032-012-0356-z.
  21. Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question? American Journal of Translational Research. 2013;5(6):563-581.
  22. Horst D, Kriegl L, Engel J, Jung A, Kirchner T. CD133 and nuclear beta-catenin: The marker combination to detect high risk cases of low stage colorectal cancer. European Journal of Cancer. 2009;45(11):2034-2040. doi:10.1016/j.ejca.2009.04.004.
  23. Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells. 2013;31(5):857-869.  doi:10.1002/stem.1317.
  24. Wang J, Li F, Zhang G, Chen Y, Hu Y, Chen X, Lu B, Zhang X. Two novel monoclonal antibodies against human CD133-2: distinct epitopes and agonist activity to enhance growth of CD133 expression cells in vitro. Hybridoma. 2010;29(3):241-249. doi:10.1089/hyb.2009.0113.
  25. Chen W, Li F, Xue ZM, Wu HR. Anti-human CD133 monoclonal antibody that could inhibit the proliferation of colorectal cancer cells. Hybridoma. 2010;29(4):305-310.  doi:10.1089/hyb.2010.0019.
  26. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary and Pancreatic Diseases International. 2007;6(1):92-97.
  27. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. International Journal of Clinical Practice. 2008;62(8):1212-1218. doi:10.1111/j.1742-1241.2008.01777.x.
  28. Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R. CD44+CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biology and Therapy. 2010;10(11):1182-1190. doi:10.4161/cbt.10.11.13664.
  29. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G. The role of CD133 in the identification and characterization of tumour-initiating cells in non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery. 2009;36:446-453.  doi:10.1016/j.ejcts.2009.03.063.
  30. Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, Matsumoto T, Inoue H, Kuwano H, Mori M. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Annals of Surgical Oncology. 2008;15(2):638-648.  doi:10.1245/s10434-007-9605-3.
  31. Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clinical Cancer Research. 2009;15(13):4299-4311. doi:10.1158/1078-0432.CCR-08-1883.
  32. La Porta C. Cancer stem cells: lessons from melanoma. Stem Cell Reviews and Reports. 2009;5(1):61-65.  doi:10.1007/s12015-008-9048-7.
  33. Jao SW, Chen SF, Lin YS, Chang YC, Lee TY, Wu CC, Jin JS, Nieh S. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Annals of Surgical Oncology. 2012;19(11):3432-3440. doi:10.1245/s10434-012-2394-3.
  34. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Kawamoto A, Yasuda H, Morimoto Y, Fujikawa H, Inoue Y, Miki C, Kusunoki M. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncology Reports. 2010;24(2):345-350.  doi:10.3892/or_00000865.
  35. Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K, Kamohara Y, Inoue H, Mori M. CD133+CD44+ Population efficiently enriches colon cancer initiating cells. Annals of Surgical Oncology. 2008;15(10):2927-2933. doi:10.1245/s10434-008-0074-0.
  36. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clinical and Developmental Immunology. 2012;2012:708036. doi:10.1155/2012/708036.
  37. Zheng J, Li Y, Yang J, Liu Q, Shi M, Zhang R, Shi H, Ren Q, Ma J, Guo H, Tao Y, Xue Y, Jiang N, Yao L, Liu W. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC Cancer. 2011;11:1-9.  doi:10.1186/1471-2407-11-251.
  38. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, Sleeman JP. CD24 Expression causes the acquisition of multiple cellular Properties associated with tumor growth and metastasis. Cancer Research. 2005;65(23):10783-10793. doi:10.1158/0008-5472.CAN-05-0619.
  39. Pors K, Moreb JS. Aldehyde dehydrogenases in cancer: an opporunity for biomaker and drug development? Drug Discovery Today. 2014;19(12):1953-1963. doi:10.1016/j.drudis.2014.09.009.
  40. Morgan CA, Hurley TD. Characterization of two distinct structural classes of selective aldehyde dehydrogenase 1A1 inhibitors. Journal of Medical Chemistry. 2015;58(4):1964-1975. doi:10.1021/jm501900s.
  41. Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, Fazli L, Gleave M, Witte ON, Garraway IP, Wu H. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS One. 2012;7(8):e42564. doi:10.1371/journal.pone.0042564.
  42. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Investigation. 2009;27(8):844-850.  doi:10.1080/07357900902744502.
  43. Sperling C, Schwartz S, Büchner T, Thiel E, Ludwig WD. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica. 1997;82(5):617-621.
  44. Wei C, Guomin W, Yujun L, Ruizhe Q. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biology and Therapy. 2007;6(5):763-768.  doi:10.4161/cbt.6.5.3996.
  45. Oktem G, Bilir A, Uslu R, Inan SV, Demiray SB, Atmaca H, Ayla S, Sercan O, Uysal A. Expression profiling of stem cell signaling alters with spheroid formation in CD133high/CD44high prostate cancer stem cells. Oncology Letters. 2014;7(6):2103-2109. doi:10.3892/ol.2014.1992.
  46. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. International Journal of Cancer. 2010;126(9):2067-2078. doi:10.1002/ijc.24868.
  47. Rocco A, Liguori E, Pirozzi G, Tirino V, Compare D, Franco R, Tatangelo F, Palaia R, D'Armiento FP, Pollastrone G, Affuso A, Bottazzi EC, Masone S, Persico G, Nardone G. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. Journal of Cell Physiology. 2012;227(6):2686-2693. doi:10.1002/jcp.23013.
  48. Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma — their prognostic significance. Pathology International. 2012;62(12):792-801.  doi:10.1111/pin.12019.
  49. Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, Sentani K, Oue N, Yasui W. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathology International. 2012;62(2):112-119.  doi:10.1111/j.1440-1827.2011.02760.x.
  50. Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW, Yun JP, Chen YB, Cai MY. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. Journal of Surgical Oncology. 2013;107(8):799-806.  doi:10.1002/jso.23337.
  51. Le H, Zeng F, Xu L, Liu X, Huang Y. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Molecular Medicine Reports. 2013;8(5):1511-1518. doi:10.3892/mmr.2013.1667.
  52. Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz De Leon M, Di Gregorio C, Barresi V, Scannone D, Danese S, Cittadini A, Sgambato A. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Scandinavian Journal of Gastroenterology. 2012;47(10):1211-1217. doi:10.3109/00365521.2012.694904.
  53. Wen L, Chen XZ, Yang K, Chen ZX, Zhang B, Chen JP, Zhou ZG, Mo XM, Hu JK. Prognostic value of cancer Stem cell marker CD133 expression in gastric cancer: A Systematic Review. PLOS One. 2013;8(3):e59154. doi:10.1371/journal.pone.0059154.
  54. Zhou Q, Chen A, Song H, Tao J, Yang H, Zuo M. Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. International Journal of Clinical and Experimental Medicine. 2015;8(3):3080-3088.
  55. Qu H, Li R, Liu Z, Zhang J, Luo R. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. International Journal of Clinical and Experimental Pathology. 2013;6(11):2644-2650.
  56. Chen S, Song X, Chen Z, Li X, Li M, Liu H, Li J. CD133 Expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2013;8(2):e56380. doi:10.1371/journal.pone.0056380.
  57. Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L. The clinicopathologic and prognostic significance of CD44+/CD24–/low and CD44–/CD24+ tumor cells in invasive breast carcinomas. Human Pathology. 2008;39(7):1096-1102. doi:10.1016/j.humpath.2007.12.003.
  58. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalman G. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate. 2010;70(8):875-882.  doi:10.1002/pros.21121.
  59. Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: A retrospective study of prognostic factor analysis from the viewpoint of forthcoming (Seventh) New TNM classification. Journal of Thoracic Oncology. 2010;5(5):649-657.  doi:10.1097/JTO.0b013e3181d5e554.
  60. Hofner T, Macher-Goeppinger S, Klein C, Schillert A, Eisen C, Wagner S, Rigo-Watermeier T, Baccelli I, Vogel V, Trumpp A, Sprick MR. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urological Oncology. 2014;32(5):678-686.  doi:10.1016/j.urolonc.2014.01.001.
  61. Kim YS. Influence of aldehyde dehydrogenase 1 expression on the clinical outcomes in breast cancer. Cancer Cell and Microenvironment. 2014;1:e364. doi:10.14800/ccm.364.
  62. Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N, Noguchi S. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009;100(6):1062-1068. doi:10.1111/j.1349-7006.2009.01151.x.
  63. Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF, Yang XJ, Zhang X, Cui YH, Bian XW, Yu SC. ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. BMC Cancer. 2014;14:444.  doi:10.1186/1471-2407-14-444.
  64. Zhou C, Sun B. The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: A meta-analysis. Oral Oncology. 2014;50(12):1144-1148. doi:10.1016/j.oraloncology.2014.08.018.
  65. Zhong Y, Shen S, Zhou Y, Mao F, Guan J, Lin Y, Xu Y, Sun Q. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24– phenotype. Medical Oncology. 2014;31(3):864.  doi:10.1007/s12032-014-0864-0.
  66. Currie MJ, Beardsley BE, Harris GC, Gunningham SP, Dachs GU, Dijkstra B, Morrin HR, Wells JE, Robinson BA. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Human Pathology. 2013;44(3):402-411.  doi:10.1016/j.humpath.2012.06.004.
  67. Hashimoto K, Shimizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, Aoqi K. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome. Oncology. 2012;82(3):168-174.  doi:10.1159/000336078.
  68. Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Research. 2013;15(5):R77.  doi:10.1186/bcr3471.
  69. Lin CH, Chen WT, Liu CH, Tsai HP, Wu CC, Chai CY. Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors. Virchows Archiv. 2012;460(5):447-453.  doi:10.1007/s00428-012-1210-6.
  70. Kojima M, Ishii G, Atsumi N, Nishizawa Y, Saito N, Ochiai A. CD133 expression in rectal cancer after preoperative chemoradiotherapy. Cancer Science. 2010;101(4):906-912.  doi:10.1111/j.1349-7006.2009.01478.x.
  71. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. International Journal of Cancer. 2010;126(4):950-958.  doi:10.1002/ijc.24822.
  72. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clinical Cancer Research. 2009;15(12):4234-4241. doi:10.1158/1078-0432.CCR-08-1479.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.